Will the results be positive?
The intrinsic forecast suggests a 45% chance of a positive outcome, which is close to the market price of 50.77% for YES. Given the low confidence in the forecast (60%) and no current holdings in YES or NO, the best...
The intrinsic probability of a positive result is significantly higher than the market's implied probability of 50.28%. The trial design is robust, and the drug is a biosimilar/generic version of a well-understood...
Market price (~0.503) is essentially aligned with my modest intrinsic view (~0.51). The expected edge is too small to overcome transaction costs and uncertainty. No portfolio positions exist to sell.
The intrinsic probability of a positive result is high (~85%) due to the treat-to-target design and validated once-weekly insulin mechanism. At ~50%, the market drastically underprices success.
Intrinsic 62% YES >> 50% market price. Clear edge justifies max buy within $624 cap. No position, ample cash. Low constraint risk.
